What is BIOXIS Pharmaceuticals?
BIOXIS Pharmaceuticals is a key player in the discovery, development, production, and commercialization of innovative regenerative medical products. The company's primary focus is on advancing solutions for dermatology and medical aesthetics, aiming to enhance patient care and transform the aesthetic medicine landscape. As a rapidly expanding entity, BIOXIS is committed to introducing novel ideas and popular products, including its notable offerings such as MTI-12, an ultra-pure chitosan tissular inductor, and Cytosial, a monophasic hyaluronic acid matrix.
How much funding has BIOXIS Pharmaceuticals raised?
BIOXIS Pharmaceuticals has raised a total of $2.8M across 1 funding round:
Unspecified
$2.8M
Unspecified (2016): $2.8M with participation from Juvamed
Key Investors in BIOXIS Pharmaceuticals
Juvamed
Juvamed, a manufacturing company based in Slovakia, specializes in the production of teas and regenerative creams. Their involvement suggests a strategic interest in BIOXIS Pharmaceuticals' product development and manufacturing capabilities within the regenerative medicine space.
What's next for BIOXIS Pharmaceuticals?
With the recent major strategic investment, BIOXIS Pharmaceuticals is poised for accelerated expansion and innovation. The substantial capital infusion is expected to fuel the scaling of its operations, enhance its research and development pipeline for novel regenerative therapies, and broaden its market reach in dermatology and medical aesthetics. This strategic backing signals confidence in BIOXIS's business model and its potential to lead in the evolving medical device industry, likely focusing on commercializing existing products and developing next-generation solutions.
See full BIOXIS Pharmaceuticals company page
